文献速递腹部CT

CT影像组学用于区分人表皮生长因子受体2阴性胃癌

CT Radiomics for Distinction of Human Epidermal Growth Factor Receptor 2 Negative Gastric Cancer.
PubMed 文献 · Acad Radiol · 2020-04-15

回顾性纳入132例接受根治性胃切除术的晚期胃癌患者,术前行增强CT检查,随机分为训练组90例和测试组42例,基于动脉期和门脉期图像提取影像组学特征。动脉期模型区分HER2阴性胃癌的AUC在训练组为0.756、测试组为0.830,门脉期模型AUC分别为0.715和0.718。基于标准诊疗CT的影像组学模型有希望区分HER2阴性胃癌。

要点

  • 动脉期影像组学模型区分HER2阴性胃癌的测试组AUC为0.830。
  • 门脉期模型测试组AUC为0.718,低于动脉期模型。
  • 研究为回顾性设计,样本来自单中心连续病例。

诊断标准与关键数值

  • 动脉期影像组学模型区分HER2阴性胃癌的AUC在训练组为0.756(95%CI 0.656-0.840),在测试组为0.830(95%CI 0.678-0.930)。
  • 门脉期影像组学模型区分HER2阴性胃癌的AUC在训练组为0.715(95%CI 0.612-0.804),在测试组为0.718(95%CI 0.554-0.849)。

临床应用与阅片要点

  • 动脉期影像组学模型在测试组区分HER2阴性胃癌的AUC为0.830,门脉期模型测试组AUC为0.718。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: The purpose of this study was to investigate the role of computed tomography (CT) radiomics for the prediction of the human epidermal growth factor 2 (HER2) status in patients with gastric cancer.

METHODS: One hundred and thirty two consecutive patients with advanced gastric cancer undergoing radical gastrectomy were retrospectively reviewed. All patients received preoperative contrast CT examination, and immunohistochemistry results of their HER2 status were available. All the subjects were randomly divided into a training cohort (n = 90) and a test cohort (n = 42). Arterial phase (AP) and portal phase (PP) contrast CT images were retrieved for tumor segmentation and feature extraction. Receiver operating characteristics (ROC) curves and area under the curve (AUC) were used to evaluate the performance of the radiomics classifiers.

RESULTS: Among the 132 patients, a total of 99 patients were HER2 negative, and the remaining 33 patients were border line or positive. The AP radiomics model could distinguish HER2-negative cases with an AUC of 0.756 (95% confidence interval [CI]: 0.656-0.840) in the training cohort, which was confirmed in the test cohort with AUC of 0.830 (95% CI: 0.678-0.930). The PP radiomics model showed AUCs of 0.715 (95% CI: 0.612-0.804) and 0.718 (95% CI: 0.554-0.849) in the training and test cohort for distinction of negative HER2 cases, respectively.

CONCLUSION: Radiomics models based on standard-of-care CT images hold promise for distinguishing HER2-negative gastric cancer.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Wang Y, Yu Y, Han W, et al. CT Radiomics for Distinction of Human Epidermal Growth Factor Receptor 2 Negative Gastric Cancer. Acad Radiol. 2020. PMID: 32303442. doi:10.1016/j.acra.2020.02.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。